Comparison of Metformin versus Rosiglitazone in Patients with Acanthosis Nigricans: A Pilot Study
October 2006 | Volume 5 | Issue 9 | Original Article | 884 | Copyright © 2006
Paula Bellot-Rojas MD, Rosalinda Posadas-Sanchez MSc, Nacu Caracas-Portilla MD, Jose Zamora-Gonzalez MSc, Guillermo Cardoso-Saldaña PhD, Fermin Jurado-Santacruz MD, Carlos Posadas-Romero MD
Background: Acanthosis nigricans (AN) is a skin condition commonly present on the neck of obese subjects. Obesity is often accompanied by insulin resistance and/or hyperinsulinemia. Metformin and rosiglitazone are 2 pharmacologic agents useful in conditions characterized by insulin resistance. Objective: The aim of our study was to compare the efficacy of metformin versus rosiglitazone on AN lesions of the neck as well as their effects on metabolic and anthropometric variables. Methods: This 12-week randomized, open-label pilot study involved overweight or obese subjects with AN treat with either metformin (n=14) or rosiglitazone (n=13). Results: Only the rosiglitazone group showed a significant reduction in insulin levels. No effect on the severity of AN was observed, but modest improvements of skin texture occurred in both treatment groups. Conclusions: Metformin and rosiglitazone were well-tolerated. Although efficacy on skin lesions was very modest, their use in acanthotic subjects might be useful during longer treatment periods.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close